Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Fundació Privada Eugin

Status and phase: Completed; Phase 4

Conditions: Infertility

Treatments: Drug: Progevera; Drug: Orgalutran

Study type: Interventional

Funder types: Other

Identifiers

NCT02796105

BRAKE

Details and patient eligibility

About

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Enrollment: 232 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Oocyte donors included in the oocyte donation program of Clinica EUGIN.
• 1st oocyte donation cycle at Clínica EUGIN.

Exclusion criteria

• Polycistic Ovarian syndrome (PCOs).
• Estradiol levels on day 2 of menstrual cycle >70 pg/ml.
• Hormone treatments up to 3 months before the oocyte donation cycle.
• Medical contraindication to the treatments used in the study

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

232 participants in 2 patient groups

Progevera

Experimental group

Description:

Progevera 10 mg

Treatment:

Drug: Progevera

Orgalutran

Active Comparator group

Description:

Orgalutran 0.25 mg

Treatment:

Drug: Orgalutran